The human endocrine system is a complex network of glands and organs that release hormones, acting as chemical messengers in the body. These hormones regulate distant target organs, such as the stomach and liver. Endocrine therapy, also known as hormone therapy, involves manipulating the hormones to treat various conditions like diabetes, breast cancer, postmenopausal symptoms, and contraception. This therapy focuses on either blocking or enhancing the action of specific hormones or the organs that produce them. Aromatase inhibitors like anastrozole, exemestane, and letrozole reduce estrogen synthesis by inhibiting the aromatase enzyme. Selective estrogen receptor modulators (SERMs) like toremifene and tamoxifen, as well as selective estrogen receptor degraders (SERDs) like fulvestrant, directly target the estrogen receptor.
The global market for endocrine therapy drugs (ETDs) is projected to grow due to the rising prevalence of chronic illnesses like breast cancer and diabetes. Research and development efforts in developing new ETDs for treating these diseases are also contributing to the market's growth. Furthermore, key market players are actively seeking approval for their ETD applications, further propelling the market's expansion.
In 2022, the global market for Endocrine Therapy Drugs (ETDs) is projected to reach a value of US$ 28,958.4 million, with a predicted compound annual growth rate (CAGR) of 5.1% during the forecast period of 2022 to 2030.
Major Players in the Endocrine Theraphy Drug Industry:
Novo Nordisk A/S
Novo Nordisk was established in 1923 and is headquartered in Bagsværd, Denmark. It operates in over 170 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals. In 2021, Novo Nordisk announced that the US Food and Drug Administration (FDA) had approved Wegovy™.
Pfizer Inc.
Pfizer Inc. was established in 1849 and is headquartered in New York, United States. It operates in 181 countries and is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals. In 2021, Pfizer Inc. received U.S. Food and Drug Administration (FDA) approval for their supplement new drug application for MYFEMBREE, an endocrine therapy drug for pain management associated with endometriosis.